CROI 2019 is here and we want to be sure YOU know where to find us in Seattle. Below is the list of faculty presentations and posters from our Division. Find us on Twitter @UNMC_ID
Content courtesy #CROI2019 http://www.croiconference.org/sites/default/files/uploads/croi2019-program-and-information.pdf
Oral presentations:
Tuesday March 5 2019 (Oral Abstract O-05 STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING Room 6AB 10:00 AM – 12:00 PM)
Abstract 51: DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ
Kimberly K. Scarsi, Lauren Cirrincione, Shadia Nakalema, Kristin Darin, Ian Musinguzi, Isabella Kyohairwe, Pauline Byakika-Kibwika, Andrew Owen, Lee Winchester, Anthony Podany, Susan E. Cohn, David Back, Courtney V. Fletcher, Marco Siccardi, Mohammed Lamorde
Abstract 52: PHARMACOGENETICS WORSENS AN ADVERSE ANTIRETROVIRALHORMONAL CONTRACEPTIVE INTERACTION
David Haas, Yoninah S. Cramer, Catherine Godfrey, Susan L. Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert Coombs, Kristine Coughlin, Laura E. Moran, David Gingrich, Carmen D. Zorrilla, Paxton Baker, Susan E. Cohn, Kimberly K. Scarsi, for the AIDS Clinical Trials Group A5316 Study Team
Wednesday March 6 2019 10am-12pm (Oral Abstract O-07 TB: FROM CONTACT TO CURE AND BEYOND Room 6AB)
Abstract 82: EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINST MULTIDRUG-RESISTANT TB
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Eric Nuermberger, Laura E. Moran, Kathleen Donahue, Susan Swindells, Andreas H. Diacon, for the ACTG A5312 Study Team
Wednesday March 6 2019, (Oral Abstract O-08 HEPATITIS C: NOW YOU SEE ME; SOON YOU WON’T Room 6C 10:00 AM – 12:00 PM)
Abstract 87: A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS
Catherine A. Chappell, Elizabeth E. Krans, Katherine Bunge, Ingrid Macio, Debra Bogen, Kimberly K. Scarsi, Leslie A. Meyn, Sharon L. Hillier
Wednesday March 6 2019,Oral Abstract O-10 NEW OPTIONS AND OPPORTUNITIES IN PrEP Auditorium – 4AB
Abstract 103: LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIRALAFENAMIDE VS -DISOPROXIL FUMARATE
Courtney V. Fletcher, Ann Thorkelson, Kayla Campbell, Lee Winchester, Timothy Mykris, Jon Weinhold, Jodi Anderson, Jacob Zulk, Puleng Moshele, Siri Jorstad, Anthony Podany, Jason V. Baker, Timothy Schacker
Wednesday March 6 2019, 10am-12pm (Oral Abstract O-13 ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE Room 6AB)
Abstract 139: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS
Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J. Richmond, Giuliano Rizzardini, Axel Baumgarten, Maria Del Mar Masia, Gulam Latiff, Vadim Pokrovsky, Joseph M. Mrus, Jenny O. Huang, Krischan J. Hudson, David A. Margolis, Kimberly Smith, Peter E. Williams, William Spreen
******
Themed Discussions
Wednesday March 6 2019: TD-08 WEIGHT GAIN DURING ART Room 6AB 1:30-2:30PM
Abstract 669: RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ART
Jordan E. Lake, Kunling Wu, Kristine M. Erlandson, Sara H. Bares, Paula Debroy, Catherine Godfrey, John R. Koethe, Grace A. McComsey, Frank J. Palella, Katherine Tassiopoulos
Abstract 673: THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART
Sara H. Bares, Laura M. Smeaton, Vincent Vu, Beth A. Zavoda-Smith, Sarah E. Scott, Catherine Godfrey, Grace A. McComsey
Abstract 518 IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART
Catherine Godfrey, Michael D. Hughes, Justin Ritz, Robert Gross, Robert A. Salata, Rosie Mngqibisa, Carole Wallis, Mumbi Makanga, Marije Van Schalkwyk, Mitch Matoga, Courtney V. Fletcher, Beatriz Grinsztejn, Ann Collier, for the ACTG 5288 Team
******
Poster Presentations:
Tuesday March 5 2019, 2:30-4pm (P-N1 WEIGHT GAIN DURING ART Poster Hall – 4EF )
Abstract 669: RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ART
Jordan E. Lake, Kunling Wu, Kristine M. Erlandson, Sara H. Bares, Paula Debroy, Catherine Godfrey, John R. Koethe, Grace A. McComsey, Frank J. Palella, Katherine Tassiopoulos
Abstract 673: THE IMPACT OF WEIGHT GAIN AND SEX ON IMMUNE ACTIVATION FOLLOWING INITIATION OF ART
Sara H. Bares, Laura M. Smeaton, Vincent Vu, Beth A. Zavoda-Smith, Sarah E. Scott, Catherine Godfrey, Grace A. McComsey
Tuesday March 5 2019, 2:30-4pm: (Poster P-U3 SOMETHING’S MISSING; CONTRACEPTION AND HIV Poster Hall – 4EF )
Abstract 1010: PHARMACOKINETIC AND PHARMACOGENETIC ASSESSMENT OF ART AND CONTRACEPTIVE IMPLANTS
Randy Stalter, Jared Baeten, Kimberly K. Scarsi, Bani Tamraz, Katherine Thomas, David Erikson, Jairam Lingappa, Kavita Nanda, Athena Kourtis, Rena Patel, for the Partners PrEP Study Team
Tuesday March 5 2019, 2:30-4pm: (Poster P-R5 EPIDEMIOLOGY OF TREATMENT AND SURVIVAL Poster Hall – 4EF )
Abstract 916: LOW RATE OF SEX-SPECIFIC ANALYSES IN CROI PRESENTATIONS IN 2018: ROOM TO IMPROVE
Monica Gandhi, Laura M. Smeaton, Christina Vernon, Eileen P. Scully, Sara Gianella, Selvamuthu Poongulali, Anandi N. Sheth, Marije Van Schalkwyk, Karin L. Klingman, William R. Short, Valarie S. Opollo, Susan E. Cohn, Kimberly K. Scarsi, Rosie Mngqibisa, Elizabeth Connick
Abstract 518: IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART
Catherine Godfrey, Michael D. Hughes, Justin Ritz, Robert Gross, Robert A. Salata, Rosie Mngqibisa, Carole Wallis, Mumbi Makanga, Marije Van Schalkwyk, Mitch Matoga, Courtney V. Fletcher, Beatriz Grinsztejn, Ann Collier, for the ACTG 5288 Team
Wednesday March 6 2019: Poster P-B6 HIV AND THE REPRODUCTIVE TRACT Poster Hall – 4EF 2:30 PM – 4:00 PM
Abstract 241 HIV-SUPPRESSED PATIENTS’ PLASMA AND SEMEN EXOSOMES CONTAIN PROTECTIVE LEVELS OF ART
Jennifer L. Welch, Jack T. Stapleton, Hussein Kaddour, Lee Winchester, Courtney V. Fletcher, Chioma M. Okeoma
******
Congratulations to all of our UNMC ID faculty presenting at #CROI2019! Check out their oral and poster presentations and share your thoughts with us on Twitter @UNMC_ID


Yadav et al. conducted a quasi-experimental quality improvement study to determine the impact of implementing an “Expected Practice” (EP) method to alter antibiotic prescribing practices towards favoring shorter duration of therapy (DOT). This method leverages the prescriber’s desire to meet their own institutional expectations, which may be viewed as more authoritative than external medical society guidelines. The authors chose DOT as the endpoint because clinicians were concerned about potential poor outcomes with shorter DOT.
In the 12 months after implementing EP, the average antibiotic DOT decreased by 10%, 11%, 11%, and 27% for UTI, SSTI, CAP and VAP respectively, with concomitant decreases in total antibiotic exposure measured in total milligrams administered. This impact was statistically sustained by the end of that year for UTI and CAP, but seemed to wane toward the end of the year for SSTIs and VAP.
One of the studies I will lead next year will be in assessing proper utilization of chlorhexidine. Chlorhexidine gluconate is a broadly active, biguanide antimicrobial disinfectant that appears to decrease hospital-acquired infections when it is used to bathe patients in intensive care units. However, it remains unclear what the best method is for applying CHG. We seek to evaluate two methods of CHG bathing 2% CHG impregnated cloths and 4% solution with regard to residual CHG skin concentration and quantitative skin microbial burden.
In order to provide me this opportunity the Internal Medicine department graciously awarded me the Scientist Development Award. I am honored that they selected me, in order to provide me the opportunity to continue to developing my skills as a clinical researcher. Beyond leading several studies in the upcoming year, I am looking forward to beginning work towards a Masters in Public Health with a focus in biostatistics, which I believe will further augment my training.
“Richard has been a real asset for our fellowship and it is very gratifying to see him succeed. He has worked hard to grow as an Infectious Disease clinician and scientist and this award is validation of those efforts. I am looking forward to working with Richard on his projects next year.” – Dr. Trevor Van Schooneveld (ID Fellowship Program Director, Infection Control Associate Medical Director, and one of Dr. Hankins’ mentors)
“I have been a research and career mentor for Dr. Hankins starting in his final year of residency and through fellowship thus far, and supported his completion of several projects, presentations and manuscripts. Dr. Hankins has been motivated to create an academic, research career; with ongoing guidance, he will absolutely succeed in that role and I am pleased to play a part in his career development.” – Dr. Kelly Cawcutt (Infection Control Associate Medical Director, and one of Dr. Hankins’ mentors)
“This is a terrific honor for Rich and will enable him to join the ID division faculty as an instructor and devote significant time to career development. Rich’s research project will greatly expand our knowledge regarding this important infection prevention intervention, and take advantage of UMMC faculty development opportunities to hone his teaching and research skills.” – Dr. Mark Rupp (Infectious Diseases Division Chief, Infection Control Medical Director, and Dr. Hankins’ primary mentor)
Measurement of Fever
Use of Antipyretics or cooling therapies
Recent Comments